摘要
目的观察培美曲塞联合或单药治疗晚期非小细胞肺癌的临床疗效和毒副作用。方法对30例具有可测量指标的晚期NSCLC患者使用培美曲塞500mg/m2加用顺铂60mg/m2治疗,分析全组疗效结果。结果全组病例无CR、PR病例,MR5例,SD17例,PD8例,控制率为73.3%。有4例患者肿瘤标志物癌胚抗原明显下降。总体的不良反应较轻微,无中断治疗的病例。结论培美曲塞治疗晚期NSCLC有效,患者耐受性较好。
Objective To observe the effect and side effect of pemetrexed combined or single agent in the treatment of advanced non small cell lung cancer. Methods 30 patients with the measure indices of NSCLC were treated by pemetrexed 500 mg/m 2 and cis-platinum 60 mg/m 2 ,analyzing the curative effect of patients. Results There were no CR,PR cases,5 cases of MR,17 cases of SD,8 cases of PD,the control rate was 73.3%.There was a significant decline of the tumor markers carcinoma antigen embryos of Four patients,the adverse reaction were slighted,there was no treatment interrupted cases. Conclusion The effect of pemetrexed for advanced- stage NSCLC cancer was better.The tolerability of patients was good.
出处
《中国医药科学》
2012年第18期70-70,120,共2页
China Medicine And Pharmacy
关键词
晚期非小细胞肺癌
培美曲塞
治疗
Advanced non-small cell lung cancer
Pemetrexed
Treatment
